NCT01708564View on ClinicalTrials.gov

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Hemophilia
Interventions
BIOLOGICAL

rhFVIIa

Patients will be administered low, intermediate and high doses of rhFVIIa

Trial Locations (3)

60612

RUSH Hemophilia & Thrombophilia Center, Chicago

95817

UC Davis Health System Internal Medicine: Hematology & Oncology, Sacramento

Unknown

Centre for Human Drug Research, Leiden

Sponsors

Lead Sponsor

rEVO Biologics
All Listed Sponsors
lead

rEVO Biologics

INDUSTRY

NCT01708564 - A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B | Biotech Hunter | Biotech Hunter